UPDATE: Harpoon Therapeutics (HARP) PT Lowered to $17 at Truist Securities, Following Announcement Of Management Change

October 27, 2021 11:52 AM EDT
Get Alerts HARP Hot Sheet
Price: $5.99 -9.38%

Rating Summary:
    9 Buy, 1 Hold, 0 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 0 | Down: 2 | New: 11
Trade Now! 
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.
(Updated - October 27, 2021 12:13 PM EDT)

Truist Securities analyst Asthika Goonewardene lowered the price target on Harpoon Therapeutics (NASDAQ: HARP) to $17.00 (from $31.00) while maintaining a Buy rating.

Analyst comments: "Our PT cut largely reflects a more conservative view on HPN424, as HARP adapted to the unexpectedly higher CRS for the PSMA-directed T-cell engager class. There are lessons learned, which we believe have been instrumental in guiding HARP's other clinical trials, as well as new platform adaptations. But we do not think that this experience has broader negative connotations, nor does our PT cut reflect any loss of faith in the management team."

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst PT Change